This page contains brief information about ibrutinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Ibrutinib is approved to treat:
- Chronic lymphocytic leukemia in patients who have already received other treatment.
- Mantle cell lymphoma in patients who have already received other treatment.
- Waldenström macroglobulinemia (a type of non-Hodgkin lymphoma).
Ibrutinib is also being studied in the treatment of other types of cancer.
More About Ibrutinib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Ibrutinib - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Targeted Cancer Therapies - Information about the use of this drug to treat cancer.
Clinical Trial Results: Ibrutinib Improves Survival Compared With Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia - Important clinical trial results for this drug, background information, and how the trial was done.
Investigational Targeted Drug Induces Responses in Aggressive Lymphomas - Information from the NCI Press Office about this drug.
Clinical Trials Accepting Patients
Find Clinical Trials for Ibrutinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.